Neurological Effects and Safety of Encapsulated Dexamethasone Sodium Phosphate in Pediatric Ataxia Telangiectasia: Insights from the NEAT Phase 3 Trial
Posted inClinical Updates Neurology news Pediatrics

Neurological Effects and Safety of Encapsulated Dexamethasone Sodium Phosphate in Pediatric Ataxia Telangiectasia: Insights from the NEAT Phase 3 Trial

The NEAT phase 3 trial evaluated erythrocyte-encapsulated dexamethasone sodium phosphate in children with ataxia telangiectasia aged 6–9 years, confirming safety but failing to demonstrate statistically significant neurological improvement over placebo.